Composition for enzyme inhibition
AssigneeOnyx Therapeutics, Inc.
InventorsEvan R. Lewis, Mark Nguyen Ho, Fabiana N. Fonseca
Life of this patent
Estimating the term…
Abstract
Compositions comprising one or more practically insoluble proteasome inhibitors and a cyclodextrin, particularly a substituted cyclodextrin, substantially increase the solubility of these proteasome inhibitors and facilitate their administration. Such compositions optionally comprise a buffer. Methods of treatment using such compositions are also disclosed.
Claims32
A pharmaceutical composition comprising a practically insoluble peptide epoxy ketone proteasome inhibitor or a pharmaceutically acceptable salt thereof and a substituted cyclodextrin selected from hydroxypropyl beta-cyclodextrin and sulfobutyl ether beta-cyclodextrin (SBECD).
A pharmaceutical composition comprising a compound having a structure
- or a pharmaceutically acceptable salt thereof, and a substituted cyclodextrin selected from hydroxypropyl beta-cyclodextrin and sulfobutyl ether beta-cyclodextrin (SBECD).
A pharmaceutical composition comprising a compound having a structure
- or a pharmaceutically acceptable salt thereof, in an aqueous solution containing 10% (w/v) SBECD and 10 mM citric acid adjusted to pH 3.5.
A pharmaceutical composition in the form of a lyophilisate comprising SBECD and a compound having a structure
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.